I said "if." Is there a reason that an ex-US trial has to be poorly run? They have done ex-US trials recently. You'll doubtless enlighten us if there were major screwups attributable to location.
Go on, handicap the probability of success, don't just carp.
""1. A trial conducted ex-US with FDA approved protocols will have more weight with the EMEA than one conducted in the US. (And we don't even know where ex-US is - may well be Asia)""
Market Data 
Markets 
AI
